Selecting cases for whom additional tests can improve prognostication
- PMID: 23304404
- PMCID: PMC3540468
Selecting cases for whom additional tests can improve prognostication
Abstract
Prognostic models are increasingly being used in clinical practice. The benefit of adding variables (e.g., gene expression measurements) to an original set of variables (e.g., phenotypes) when building prognostic models is usually measured on a whole set of cases. In practice, however, including additional information only helps build better models for some subsets of cases. It is important to prioritize who should undergo further testing. We present a method that can help identify those patients might benefit from additional testing. Our experiments based on limited breast cancer data indicate that relatively old patients with large tumors and positive lymph nodes constitute a group for whom prognoses can be more accurate with the addition of gene expression measurements. The same is not true for some other groups.
Figures
Similar articles
-
Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures.BMC Med Genomics. 2011 Jan 9;4:3. doi: 10.1186/1755-8794-4-3. BMC Med Genomics. 2011. PMID: 21214954 Free PMC article.
-
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.Health Technol Assess. 2019 Jun;23(30):1-328. doi: 10.3310/hta23300. Health Technol Assess. 2019. PMID: 31264581 Free PMC article.
-
Overview of resistance to systemic therapy in patients with breast cancer.Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1. Adv Exp Med Biol. 2007. PMID: 17993229 Review.
-
Mixture classification model based on clinical markers for breast cancer prognosis.Artif Intell Med. 2010 Feb-Mar;48(2-3):129-37. doi: 10.1016/j.artmed.2009.07.008. Epub 2009 Dec 14. Artif Intell Med. 2010. PMID: 20005686
-
Is gene array testing to be considered routine now?Breast. 2011 Oct;20 Suppl 3:S87-91. doi: 10.1016/S0960-9776(11)70301-0. Breast. 2011. PMID: 22015300 Review.
Cited by
-
Computational advances in cancer informatics (a).Cancer Inform. 2014 Oct 13;13(Suppl 1):45-8. doi: 10.4137/CIN.S19243. eCollection 2014. Cancer Inform. 2014. PMID: 25484572 Free PMC article. No abstract available.
-
A review of approaches to identifying patient phenotype cohorts using electronic health records.J Am Med Inform Assoc. 2014 Mar-Apr;21(2):221-30. doi: 10.1136/amiajnl-2013-001935. Epub 2013 Nov 7. J Am Med Inform Assoc. 2014. PMID: 24201027 Free PMC article. Review.
-
EXpectation Propagation LOgistic REgRession (EXPLORER): distributed privacy-preserving online model learning.J Biomed Inform. 2013 Jun;46(3):480-96. doi: 10.1016/j.jbi.2013.03.008. Epub 2013 Apr 4. J Biomed Inform. 2013. PMID: 23562651 Free PMC article.
References
-
- Retèl VP, Joore Ma, Knauer M, et al. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. European Journal of Cancer (Oxford, England : 1990) 2010;46:1382–91. - PubMed
-
- Dunkler D, Michiels S, Schemper M. Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis? European journal of cancer (Oxford, England : 1990) 2007;43:745–51. - PubMed
-
- van’t Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature. 2008;452:564–70. - PubMed
-
- Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. The New England Journal of Medicine. 2004;351:2817–26. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical